A comprehensive report on the 1st Swiss-EUCAST Antimicrobial Susceptibility Testing (AST) Meeting

Clicks: 22
ID: 329533
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #179 of 241 articles by views in FEMS microbiology letters

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 241 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Antimicrobial susceptibility testing (AST) is being reshaped by increasingly complex resistance mechanisms, revised interpretive frameworks, and rapid phenotypic and genomic technologies. The first Swiss-EUCAST AST Meeting, held in Zurich on 4 May 2026, brought together more than 100 clinical microbiologists, researchers, and infectious diseases specialists to discuss how these developments should be translated into routine diagnostics. The meeting focused on three topics: the limitations of genotype-phenotype prediction, the ongoing need for standardized interpretation within the European Committee on Antimicrobial Susceptibility Testing (EUCAST), and the potential of new technologies to reduce turnaround times. Discussions specifically on Pseudomonas aeruginosa, as well as on pathogens without clinical breakpoints, carbapenemase-producing Enterobacterales, expected phenotypes, epidemiological cutoff values, rapid phenotypic susceptibility tests, and whole-genome sequencing, showed that no single method can eliminate all diagnostic uncertainties. In summary, it was concluded that standardized phenotypic ASTs will continue to serve as a clinical reference in the future, but molecular and genomic methods offer additional advantages in terms of speed, as well as insights into mechanisms of action and epidemiological relations.
Reference Key
openalex_W7214111388 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Hendrik Koliwer‐Brandl, Stefano Mancini, Barbara Juliane Holzknecht, Rafael Cantón, Laurent Poirel, Helena Seth-Smith, Sören G. Gatermann, Marlène Amara, Carmen Ardanuy, Oliver Nolte, Adrian Egli
Are you one of these authors? Claim your profile
Journal FEMS microbiology letters
Year 2026
DOI
10.1093/femsle/fnag109
URL
https://doi.org/10.1093/femsle/fnag109
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.